In vivo selection of anti-glioblastoma DNA aptamers in an orthotopic patient-derived xenograft model
NAR Cancer · 2025
DOI: 10.1093/narcan/zcaf005 ↗Kurz gefasst
Fachartikel in der Zeitschrift NAR Cancer, 2025. Verfasst von Caroline D Doherty und 8 weiteren Autor:innen. Beteiligte Einrichtung: D epartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic Graduate School of Biomedical Sciences, Rochester, MN 55905, United …. Hauptthemen laut MEDLINE: Aptamers, Nucleotide, Glioblastoma, Brain Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NINDS NIH HHS, NCATS NIH HHS, Mayo Clinic.
Abstract (Originalsprache)
Glioblastoma (GBM) is the most common and aggressive primary malignant brain tumor of adults. Current therapeutic options yield dismal prognoses that have remained essentially unchanged over nearly two decades. Diffuse growth patterns, high intratumoral heterogeneity, and variable blood–brain barrier integrity limit treatment efficacy, creating challenges that rational small molecule design has not overcome. Antibody–drug conjugates have shown some promise, leading us to hypothesize that smaller folded DNA aptamers, developed in vivo via principles of natural selection, might eventually have advantages for drug delivery. Here, we document the first in vivo DNA aptamer selection involving an orthotopic patient-derived xenograft GBM mouse model to identify tumor-homing DNA aptamers. We demonstrate the preferential accumulation of these aptamers in the tumor relative to other tissues 4 h after intraperitoneal injection. The aptamers can be detected by quantitative polymerase chain reaction, fluorescent tumor staining, and stain GBM tumor section from untreated mice and the GBM tumor cells in culture. Two of three candidates are selective for the target cell line in vitro and do not bind other human tumor cells. In vivo selection of tumor-specific DNA aptamers demonstrates a novel approach for diagnostics or toxin delivery that might allow for the development of individualized therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- D epartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic Graduate School of Biomedical Sciences, Rochester, MN 55905, United States.
- Department of Biochemistry and Molecular Biology, Mayo Clinic Graduate School of Biomedical Sciences, Rochester, MN 55905, United States.
- Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, United States.
- Summer Undergraduate Research Fellowship, Mount Holyoke College, South Hadley, MA, 01075 United States.
ORCID-Profile: Louis J Maher
Förderung
- NINDS NIH HHS
- NCATS NIH HHS
- Mayo Clinic
- NIH
Zitieren
APA
Doherty, C. D., Wilbanks, B. A., Jain, S., S Pearson, K., Bakken, K. K., Burgenske, D. M., Lett, N. W., Sarkaria, J. N., & Maher, L. J. (2025). In vivo selection of anti-glioblastoma DNA aptamers in an orthotopic patient-derived xenograft model. NAR Cancer. https://doi.org/10.1093/narcan/zcaf005
Vancouver
Doherty CD, Wilbanks BA, Jain S, S Pearson K, Bakken KK, Burgenske DM, et al. In vivo selection of anti-glioblastoma DNA aptamers in an orthotopic patient-derived xenograft model. NAR Cancer. 2025. doi:10.1093/narcan/zcaf005
BibTeX
@article{Doherty2025,
author = {Doherty, Caroline D and Wilbanks, Brandon A and Jain, Sonia and S Pearson, Keenan and Bakken, Katie K and Burgenske, Danielle M and Lett, Nay Won and Sarkaria, Jann N and Maher, Louis J},
title = {In vivo selection of anti-glioblastoma DNA aptamers in an orthotopic patient-derived xenograft model},
journal = {NAR Cancer},
year = {2025},
doi = {10.1093/narcan/zcaf005}
}
EUVIMED